Drug reference
Treatment of high-grade, resectable, non-metastatic osteosarcoma after complete surgical resection (in combination with chemotherapy) ▶BY INTRAVENOUS INFUSION ▶Adult: Infusion to be given over 1 hour (consult product literature or local protocols) l UNLICENSED USE Not licensed for use in patients over 30 years of age at initial diagnosis.
PDF page 1032
Asthma—consider prophylactic bronchodilator therapy. chronic obstructive pulmonary disease—consider prophylactic bronchodilator therapy. history of autoimmune disease. history of collagen disease. history of inflammatory disease
PDF pages 1032, 1033
NICE decisions ▶Mifamurtide for the treatment of osteosarcoma (October 2011) NICE TA235 Mifamurtide (Mepact ®) in combination with postoperative multi-agent chemotherapy is recommended (within its licensed indication), as an option for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection in children, adolescents and young adults and when mifamurtide is made available at a reduced cost to the NHS under the patient access scheme. www.nice.org.uk/guidance/ta235
PDF page 1033
→Appendix 1: mifamurtide
PDF page 1033
▶Common or very common Alopecia. anaemia. anxiety. appetite decreased. arthralgia. asthenia. cancer pain. chest discomfort. chills. confusion. constipation. cough. cyanosis. dehydration. depression. diarrhoea. dizziness. drowsiness. dysmenorrhoea. dyspnoea. feeling cold. fever. flushing. gastrointestinal discomfort. haemorrhage . headache. hearing loss. hepatic pain. hyperhidrosis. hypertension. hypokalaemia. hypotension. hypothermia. increased risk of infection. insomnia. laryngeal pain. leucopenia. malaise. mucositis. muscle complaints. musculoskeletal stiffness. nasal congestion. nausea. neutropenia. oedema. pain. pallor. palpitations. respiratory disorders. sensation abnormal. sepsis. skin reactions. tachycardia. thrombocytopenia. tinnitus. tremor. urinary disorders. vertigo. vision blurred. vomiting. weight decreased
PDF page 1033
Effective contraception required.
PDF page 1033
Avoid.
PDF page 1033
Avoid—no information available.
PDF page 1033
Manufacturer advises caution in moderate impairment (risk of increased half-life and exposure); avoid in severe impairment (no information available).
PDF page 1033
Use with caution—no information available.
PDF page 1033
▶Monitor renal function, hepatic function and clotting parameters. ▶Monitor patients with history of venous thrombosis, vasculitis, or unstable cardiovascular disorders for persistent or worsening symptoms during administration—consult product literature.
PDF page 1033
There can be variation in the licensing of different medicines containing the same drug. Powder for suspension for infusion ▶Mepact (Takeda UK Ltd) Mifamurtide 4 mg Mepact 4mg powder for suspension for infusion vials | 1 vial P £2,375.00 IMMUNOSUPPRESSANTS › THALIDOMIDE AND RELATED ANALOGUES
PDF page 1033
Infusion to be given over 1 hour (consult
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1032
